Clinical Trials Browser

Phase 1/2 × INDUSTRY × etirinotecan pegol × Clear all

NCT05158491 2022-01-05

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

Phase 1/2 Unknown

Small Cell Lung Carcinoma